This disease is not new in India but has revisited for the third time after previously outbreaking in the two districts of West Bengal – Siliguri and Nadia in 2001 and 2007 respectively. High fatality rate (about 70 percent) and easy person-to-person transmission of the disease had already been established during its previous encounters but still, there is no vaccine for the prevention or cure of the disease and only supportive treatment is given for the disease-related complications including neurological and respiratory complications.
The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.
Genprex raised $6.4 million in IPO at a share price of $5.
Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.
Israeli startup Nutrino raised $8 million in their Series A funding round led by the existing investor New York Angels. According to the Medgenera report, the investment funding in health analytics is estimated to reach around $4.4 billion in 2018 at about 65.7% CAGR during 2015-2018.
Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.